CN115484945A - 治疗脑病症的方法 - Google Patents

治疗脑病症的方法 Download PDF

Info

Publication number
CN115484945A
CN115484945A CN202080096923.5A CN202080096923A CN115484945A CN 115484945 A CN115484945 A CN 115484945A CN 202080096923 A CN202080096923 A CN 202080096923A CN 115484945 A CN115484945 A CN 115484945A
Authority
CN
China
Prior art keywords
nac
brain
subject
dose
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096923.5A
Other languages
English (en)
Chinese (zh)
Inventor
道格拉斯·A·格林
拉吉夫·R·拉坦
托马斯·I·布拉德肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Burke Institute Of Neurology
Nuronezel
Original Assignee
Burke Institute Of Neurology
Nuronezel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burke Institute Of Neurology, Nuronezel filed Critical Burke Institute Of Neurology
Publication of CN115484945A publication Critical patent/CN115484945A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080096923.5A 2019-12-18 2020-12-18 治疗脑病症的方法 Pending CN115484945A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949640P 2019-12-18 2019-12-18
US62/949,640 2019-12-18
US202062970254P 2020-02-05 2020-02-05
US62/970,254 2020-02-05
PCT/US2020/066179 WO2021127541A1 (en) 2019-12-18 2020-12-18 Methods of treating brain disorders

Publications (1)

Publication Number Publication Date
CN115484945A true CN115484945A (zh) 2022-12-16

Family

ID=76437600

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096923.5A Pending CN115484945A (zh) 2019-12-18 2020-12-18 治疗脑病症的方法

Country Status (7)

Country Link
US (3) US12090130B2 (https=)
EP (1) EP4076425A1 (https=)
JP (1) JP2023518635A (https=)
CN (1) CN115484945A (https=)
AU (1) AU2020407239B2 (https=)
CA (1) CA3165422A1 (https=)
WO (1) WO2021127541A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380291A1 (en) * 2019-11-04 2022-05-26 Neuronasal, Inc. Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2022067232A1 (en) * 2020-09-28 2022-03-31 Commercial Automation, Llc Food product storage and vending kiosk
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20180344678A1 (en) * 2017-05-02 2018-12-06 Burke Medical Research Institute Use of n-acetylcysteine to treat cns disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2749552B1 (en) 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
CA2871774C (en) 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
BR112017025499A2 (pt) 2015-05-28 2018-08-07 Baylor College Medicine benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20180344678A1 (en) * 2017-05-02 2018-12-06 Burke Medical Research Institute Use of n-acetylcysteine to treat cns disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Also Published As

Publication number Publication date
US12414929B2 (en) 2025-09-16
CA3165422A1 (en) 2021-06-24
US20240390313A1 (en) 2024-11-28
EP4076425A1 (en) 2022-10-26
US12090130B2 (en) 2024-09-17
WO2021127541A1 (en) 2021-06-24
US20210186911A1 (en) 2021-06-24
JP2023518635A (ja) 2023-05-08
AU2020407239B2 (en) 2025-11-27
AU2020407239A1 (en) 2022-07-28
US20260007626A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
US12414929B2 (en) Methods of treating brain disorders
US20250127712A1 (en) Compositions and methods for the treatment of opioid overdose
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US8920373B2 (en) Reduced volume formulation of glatiramer acetate and methods of administration
Tanne et al. Severe tramadol overdoses in children: a case series admitted to paediatric intensive care unit
US20240024267A1 (en) Methods of administering glutathione precursors
US12594254B2 (en) Intranasal administration of n-acetylcysteine and uses thereof
CN114828960A (zh) 治疗儿童个体的cln2病的方法
Deslandes et al. Rapid medicines management for healthcare professionals
Aloyan et al. A Breath of Relief: Oxymetazoline and Flunisolide Nasal Spray in the Management of Myasthenia Gravis Ptosis
KURMI et al. Role Of Drug Intake In Disease Caused In Central Nervous System.
TW202342049A (zh) 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法
HK40077860A (en) Methods for treating cln2 disease in pediatric subjects
Ivaturi Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221216